Stage III Pancreatic Cancer Clinical Trial
Official title:
Open-label, Single-center, Non-randomized, Phase I, Dose-ranging Study of Endoscopic Ultrasound (EUS) Guided Photodynamic Therapy (PDT) With Photofrin® in Locally Advanced Pancreatic Cancer
Verified date | December 2018 |
Source | Indiana University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase I trial studies the side effects and best dose of ultrasound-guided photodynamic therapy with porfimer sodium when given together with gemcitabine hydrochloride in treating patients with locally advanced pancreatic cancer. Photodynamic therapy uses a drug, porfimer sodium, that becomes active when it is exposed to a certain kind of light. When the drug is active, cancer cells are killed. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving photodynamic therapy together with gemcitabine hydrochloride may be effect in patients with pancreatic cancer.
Status | Completed |
Enrollment | 12 |
Est. completion date | October 28, 2018 |
Est. primary completion date | July 13, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Unresectable, locally advanced measurable (at least bidirectional) adenocarcinoma of the pancreas (regardless of site) proven by biopsy or cytology and confirmed by surgical consultation - Informed consent and authorization for the release of health information signed by the patient - Karnofsky performance status >= 70% - Life expectancy >= 3 months - Females of childbearing potential and males must use an effective method of contraception Exclusion Criteria: - Metastatic (stage IV) disease (including involvement of the colon, adrenals, or kidney, or radiographic evidence of peritoneal seeding or pulmonary metastases) - Previous chemotherapy, radiotherapy of other treatment for PC - Gastric or duodenal wall invasion by the primary PC as assessed by CT or MRI and EUS staging - Gastric or duodenal ulcer (at least 10 mm in size) within 10 mm of expected endoscopy puncture site(s) for PDT - Esophageal or gastric varices - Cystic component >= 25% the total volume of the tumor - Ascites detected by CT, ultrasound (US) or MRI; (trace ascites will not be an exclusion) - Bulky celiac adenopathy (i.e., >= 2.5 cm in diameter) - Diagnosis of islet cell tumor, lymphoma, metastatic lesion, acinar cell (or other atypical pathologic malignancy) - History of other malignancy in the past 2 years except carcinoma in situ of the cervix or bladder, non-melanomatous skin cancer or localized/early stage prostate cancer - Unable to receive or previously intolerant of moderate and/or deep sedation - Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >= 3 x upper limit of normal (ULN) - Total bilirubin >= 3 x ULN - Alkaline phosphatase >= 3 x ULN - International normalized ratio (INR) >= 1.5 - Partial thromboplastin time (PTT) ratio >= 1.5 - Serum creatinine >= 2.0 mg/dL - Hematocrit =< 28% or hemoglobin =< 9 g/dL, but may have red blood cell (RBC) transfusion - Platelet count =< 100,000/microliter (uL) - Absolute neutrophil count (ANC) =< 1500/uL - Clinically significant pancreatitis within 12 weeks of treatment with protocol therapy - Contraindication to EUS-guided needle puncture into the pancreas - History of coagulopathy or known thrombophilias - Use of anticoagulants that cannot be discontinued both 5 days before and 5 days after EUS - Clinical evidence of active infection of any type, including hepatitis B or C virus - Pregnant or lactating women - Experimental medications within the last 4 weeks prior to day 1 - Any surgery (including diagnostic laparoscopy and/or biliary +/- duodenal palliative bypass for inoperable PC) within the 2 weeks prior to day 1 of study protocol - Chronic systemic corticosteroid use at superphysiologic doses (>= 10 mg prednisone per day or equivalent) - Inability to avoid exposure of skin or eyes to direct sunlight or bright indoor light for at least 30 days - Porphyria - Inability to obtain venous access in the antecubital region to administer PHO or sedation for endoscopy procedures - Significant concurrent medical or psychiatric illness which, in the opinion of the principal investigator would interfere with trial participation |
Country | Name | City | State |
---|---|---|---|
United States | IU Simon Cancer Center | Indianapolis | Indiana |
Lead Sponsor | Collaborator |
---|---|
John DeWitt | American Society for Gastrointestinal Endoscopy, Pinnacle Biologics Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluate the number of subjects with adverse events which occur when up to 3 sites within the pancreas are treated with PDT using a total dose of 50 or 100 J per site | Adverse events will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0 which uses a scale of 1 (mild) to 5 (caused death). | Up to 4 years | |
Secondary | CT- or MRI-detected volume of tumor necrosis | Will be compared using paired t-tests or Wilcoxon rank sum tests as appropriate and changes will be plotted by maximal total energy of treatment to explore for dose-response effects. | Week 2 | |
Secondary | Rates of tumor size stabilization or decease by EUS-PDT | Will be compared using paired t-tests or Wilcoxon rank sum tests as appropriate and changes will be plotted by maximal total energy of treatment to explore for dose-response effects. | Up to 4 years | |
Secondary | Objective response rate per RECIST | Up to 4 years | ||
Secondary | Surgical downstaging off of abdominal vessels or change in tumor unresectability | Up to 4 years | ||
Secondary | Change in CA 19-9 levels | Will be compared using paired t-tests or Wilcoxon rank sum tests as appropriate and changes will be plotted by maximal total energy of treatment to explore for dose-response effects. | Baseline to up to 4 years | |
Secondary | Progression-free survival | A Kaplan-Meier plot will be produced. | From the date of initial treatment to the earliest date of disease progression, resection of measurable tumor or death for patients who fail; and to the date of disease evaluation for patients who remain at risk for failure, assessed up to 4 years | |
Secondary | Overall survival | A Kaplan-Meier plot will be produced. | From the day of first treatment to the earlier of death (from any cause) and the last date of patient contact, assessed up to 4 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01959672 -
Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
|
Phase 2 | |
Terminated |
NCT02495896 -
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Terminated |
NCT02345460 -
Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study
|
Phase 2 | |
Completed |
NCT00095966 -
Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT00020345 -
Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the Pancreas
|
Phase 2 | |
Completed |
NCT02897375 -
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT01846520 -
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
|
N/A | |
Completed |
NCT01191684 -
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT02896907 -
Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
|
Early Phase 1 | |
Completed |
NCT01068327 -
Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT02307539 -
Palliative Care in Improving Quality of Life in Patients With Newly Diagnosed Pancreatic Cancer
|
N/A | |
Completed |
NCT01222689 -
Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT00028496 -
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT00026104 -
Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03899649 -
A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer
|
||
Completed |
NCT01821612 -
Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer
|
Early Phase 1 | |
Terminated |
NCT01739439 -
Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery
|
Phase 1 | |
Completed |
NCT01131234 -
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT00323583 -
Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer
|
Phase 2 | |
Terminated |
NCT00087191 -
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
|
N/A |